To determine the potential clinical impact reduced USP22 expression may have in cancer, The Cancer Genome Atlas (TCGA) data from 19 common cancer types were scrutinized (Figure 7A) and revealed that USP22 copy number alterations occur frequently in multiple cancer types, ranging from 12% in renal clear cell carcinoma to 87% in ovarian cancer. This evidence concerns the gene USP22 and ovarian carcinoma.